KRAS and pancreatic neoplasm: The response of pancreatic cancer cells to CDDO-Me was independent of K-ras mutation, since both K-ras mutant (MiaPaca2, Panc1 and Capan2) and wild-type K-ras containing BxPC3 cells were equally sensitive to CDDO-Me.